Drug Profile

Research programme: menin inhibitors - Kura Oncology

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kura Oncology
Class Antihyperglycaemics
Mechanism of Action Menin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Type 2 diabetes mellitus

Most Recent Events

13 Mar 2025 Preclinical trials in Type 2 diabetes mellitus in USA (unspecified route) prior to March 2025
13 Mar 2025 Pharmacodynamics data from a preclinical study in Type 2 diabetes mellitus released by Kura Oncology prior to March 2025
26 Feb 2025 Kura Oncology announces intention to nominate a development candidate for next-generation menin inhibitor program in diabetes in mid-2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com